Report Overview

China Angelman Syndrome Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Angelman is a rare genetic disorder that is characterized by developmental delay, severe speech impairment, seizures, and movement and balance disorders (ataxia). Angelman syndrome affects males and females in equal numbers. The global prevalence of Angelman syndrome is estimated to be approximately 1 in 12,000-20,000 people. As of now in China nearly 1000 children with Angelman syndrome have been registered across the country. In China, Angelman syndrome affects males and females in equal numbers.



Market Drivers

China is a growing market for Angelman syndrome due to an increase in the global prevalence rate (1 in 12,000-20,000 people) and increase in R&D activities. In addition to these, other factors that contribute to the growth of the market are increase in awareness of the disease and increase in healthcare expenditure towards rare disease drug development.

However, there are some restraining factors for growth of Angelman syndrome therapeutics market in China such as misdiagnosis, underdiagnosis and lack of novel therapeutics.